FDA Approves New First-Line Treatment for HER2-Positive Advanced Gastric and GEJ Cancer

The FDA has approved new first-line zanidatamab-based treatment options for certain individuals with HER2-positive advanced stomach, gastroesophageal junction (GEJ), and esophageal cancers. A major clinical trial demonstrated that the combination of zanidatamab, tislelizumab, and chemotherapy extended survival and delayed cancer progression compared to trastuzumab plus chemotherapy.